Our Mission & Vision
Translating rigorous clinical research into practical, licensable protocols for mental health and recovery.
Nourish Appalachia, Inc. is a nonprofit R&D sponsor, founded in 2024 by entrepreneur Nathaniel Martin. We develop and validate minimal-risk adjunctive therapies under rigorous clinical oversight, and hold provisional patents on novel nutraceutical formulations.
Our Team & Collaborators
Our core team is supported by a network of clinical and research professionals—including physicians, biostatisticians, and CRO partners—who provide ongoing, on-demand expertise to ensure our protocols meet the highest standards of safety and scientific rigor.
Current Focuses:
Prophylactic Treatment Model for Trauma-Related Disorders
We are developing and preparing to pilot a preventative treatment protocol designed to reduce the likelihood of post-traumatic stress symptoms following acute psychological trauma. This research is grounded in emerging data suggesting that certain compounds—when administered in proximity to traumatic exposure—may blunt or modulate the biological cascade that underlies long-term stress pathology.
The initial phase of this work will utilize a controlled preclinical model to assess behavioral and physiological outcomes following compound administration and stress induction. If successful, this would represent a novel approach to PTSD prevention, with potential downstream applications for frontline occupations, emergency responders, and survivors of violence.
Nutraceutical Adjunct to Support Sustained Abstinence in Alcohol-Use Disorder
We are pioneering the use of a non-pharmaceutical, nutraceutical intervention with well-characterized neuromodulatory and anti-inflammatory properties to support sustained abstinence in individuals recovering from alcohol-use disorder (AUD). Early relapse remains a critical barrier—especially in rural and underserved communities—where limited access to comprehensive addiction care coincides with persistent hepatic stress and craving-driven return to drinking. By administering a targeted combination of two bioactive compounds during the first month of sobriety, we aim to accelerate normalization of liver-enzyme markers, dampen craving intensity, and bolster neurochemical resilience against relapse triggers.
Auricular Neuromodulation for Withdrawal and Pain Management
We are developing a non-invasive auricular pressure device based on established point stimulation protocols used in both addiction recovery and battlefield medicine. This includes:
A protocol used in opioid withdrawal syndrome to reduce anxiety, cravings, and sleep disturbance
A protocol originally designed for non-opioid pain relief in acute trauma settings, shown to modulate pain perception without pharmacological intervention
By combining these frameworks into a single, scalable, needle-free device, we aim to provide a physical intervention that addresses both addiction treatment and opioid avoidance upstream—making this tool relevant for recovery centers, pain clinics, and frontline medical responders alike.